Bhawana Bhatt

Bhawana Bhatt focuses on PIK3CA-mutated hormone receptor-positive breast cancer and the clinical development of PI3K alpha inhibitors. Her research has characterized the frequency and functional consequences of PIK3CA mutations in hormone receptor-positive/HER2-negative breast cancer and their role in acquired resistance to endocrine therapy. She led investigations of the clinical activity of alpelisib plus fulvestrant that contributed to the FDA approval of this combination for PIK3CA-mutated advanced breast cancer. Her work advances predictive biomarker strategies and rational combinations to improve PI3K inhibitor outcomes in breast cancer.